All In Biotech

Drug Trial Radar · NCT07659379

Gotistobart Long Term Extension (LTE) Study

Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in Gotistobart Trials

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

20

Planned (sponsor's estimate)

Start

Jul 28, 2026

Primary completion

Jul 1, 2036

Study completion Jan 1, 2037

Sponsor

Lead sponsor
OncoC4, Inc.Industry
Sponsor type
Industry
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This LTE study will examine the long-term overall survival and safety of gotistobart in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • GotistobartDrug

    ONC-392 will be given following parent trial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: 240 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Texas Oncology - Fort Worth Cancer Center (USOR)

    Fort Worth, Texas

  • Texas Oncology - Northeast

    Tyler, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.